At What Price Would GlaxoSmithKline plc Be A Bargain Buy?

G A Chester explains his bargain-buy price for GlaxoSmithKline plc (LON:GSK).

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

gskPatience is one of the key attributes of a successful investor. The likes of US master Warren Buffett have been known to wait years for the right company at the right price.

Now, while buying stocks at a fair price will tend to pay off over the long term, we all love to bag a real bargain.

Today, I’m going to tell you why I believe GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) is currently in the bargain basement.

Passive income stocks: our picks

Do you like the idea of dividend income?

The prospect of investing in a company just once, then sitting back and watching as it potentially pays a dividend out over and over?

If you’re excited by the thought of regular passive income payments, as well as the potential for significant growth on your initial investment…

Then we think you’ll want to see this report inside Motley Fool Share Advisor — ‘5 Essential Stocks For Passive Income Seekers’.

What’s more, today we’re giving away one of these stock picks, absolutely free!

Get your free passive income stock pick

Historical valuation

Glaxo Wellcome and SmithKline Beecham merged in December 2000. The group released its first set of results as GlaxoSmithKline in February 2001, reporting pro forma earnings per share (EPS) of 61p.

In the following five months, before the interim results in July, GSK’s shares traded at an average price of 1,900p, giving a price-to-earnings (P/E) ratio of 31.

There was a long de-rating of the shares through the Noughties, which reached bottom with the financial crisis/bear market, and concerns about a forthcoming industry-wide ‘patent cliff’ that would see exclusivity expire on some of the world’s biggest money-spinning drugs.

Between March and May 2009, GSK’s shares traded at an average price of 1,036p, with a P/E of just below 10 on EPS of around 105p.

Patent expiries have taken their toll over the five years since. EPS has fallen from 105p to 99p, and is expected to bottom out this year at 95p. Nevertheless, the shares have risen 34% to 1,392p.

Thus, the share price increase has been driven not by EPS growth but by a rising P/E: from just below 10 in the spring of 2009 to over 14 today, as the market has become increasingly confident of GSK weathering the patent cliff and returning to earnings growth.

What price for a bargain buy today?

If we say GSK at a P/E of 10 with a share price gain of 34% over the five following years was a bargain buy, what would the company have to do over the next five years to deliver a similar return?

Well, assuming the current P/E stays the same — it seems an eminently fair rating to me — EPS would have to rise from the current-year forecast 95p to 127p five years out.

Such a rise would represent a compound annual growth rate (CAGR) of 6%. During GSK’s last growth phase — 2001-09 — the CAGR was 7%. On this basis, I reckon the shares are a bargain buy at their current level of under 1,400p.

Another take on valuation

Stephen Lamacraft, one of the team on the new fund of ace investor Neil Woodford, has recently given an interesting take on GSK’s valuation.

He reckons GSK is worth around one-and-a-half times its current market value, with the company’s consumer healthcare business representing half the market cap, if rated on the same seven times sales valuation Bayer recently paid to acquire the consumer healthcare business of Merck.

He concludes: “Now, we are not suggesting that a corporate bidder is going to pay that sort of money for Glaxo’s consumer healthcare business any time soon — it’s just an interesting way of looking at the valuation opportunity that exists in the stock currently”.

5 stocks for trying to build wealth after 50

Inflation recently hit 40-year highs… the ‘cost of living crisis’ rumbles on… the prospect of a new Cold War with Russia and China looms large, while the global economy could be teetering on the brink of recession.

Whether you’re a newbie investor or a seasoned pro, deciding which stocks to add to your shopping list can be a daunting prospect during such unprecedented times. Yet despite the stock market’s recent gains, we think many shares still trade at a discount to their true value.

Fortunately, The Motley Fool UK analyst team have short-listed five companies that they believe STILL boast significant long-term growth prospects despite the global upheaval…

We’re sharing the names in a special FREE investing report that you can download today. We believe these stocks could be a great fit for any well-diversified portfolio with the goal of building wealth in your 50’s.

Claim your free copy now

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

G A Chester has no position in any shares mentioned. The Motley Fool has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

The flag of the United States of America flying in front of the Capitol building
Investing Articles

Forecast: here’s how far the S&P 500 could crash in 2025

S&P 500 stocks are getting sold off as investors panic over economic uncertainty. But how far could the index fall?…

Read more »

Investing Articles

Is the FTSE 250 about to surge by 45%?!

The FTSE 250’s trading at a massive discount versus historical levels. Could the underappreciated growth index enjoy an upward correction…

Read more »

Runner standing at the starting point with 2025 year for starting in new year 2025 to achieve business planing and success concept.
Investing Articles

Forecast: here’s how high can the FTSE 100 could climb in 2025

The FTSE 100’s already up over 6% since the start of the year as consumer spending starts to rise, but…

Read more »

Investing Articles

Up 30% in weeks, does the BAE Systems share price still offer value?

The BAE Systems share price has been on a tear over the past couple of months. This writer sees limited…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

Hunting for shares to buy as the market trembles? Remember this!

After a choppy week in global stock markets, our writer goes back to basics in his hunt for bargain shares…

Read more »

Investing Articles

3 simple principles to help build wealth in an ISA

As a new tax year opens up new ISA allowances for many investors, our writer shares a trio of things…

Read more »

Investing Articles

US trade tariffs: what they could mean for UK shares like Ashtead, Compass Group, and Experian

US trade tariffs continue to rock global markets, and the UK is no exception. Our writer considers how a new…

Read more »

Mindful young woman breathing out with closed eyes, calming down in stressful situation, working on computer in modern kitchen.
Dividend Shares

The Trump slump has smashed these FTSE 100 shares!

After a rough week for US and UK shares, investors have been shaken. But now these FTSE 100 stocks have…

Read more »